Literature DB >> 15056457

Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice.

Luis Pennanen1, Hans Welzl, Patrizia D'Adamo, Roger M Nitsch, Jürgen Götz.   

Abstract

Neurofibrillary tangles, insoluble protein deposits composed of filamentous tau aggregates, are neuropathological hallmarks of Alzheimer's disease and familial frontotemporal dementia (FTDP-17). Transgenic mice expressing the FTDP-17 mutation P301L of tau recapitulate key features of the human pathology, that is, tau proteins aggregate and neurofibrillary tangles begin to appear in the amygdala at 6 months of age. To detect early signs of tau aggregate-associated changes, we investigated behavioral alterations and cognitive deficits in such mice using an amygdala-specific test battery for anxiety-related and cognitive behavior. P301L mice had anxiety levels not different from wild-types, but their exploratory behavior was significantly increased. Acquisition of a fear response to tone and context as well as taste aversion was comparable to wild-types. However, extinction of a conditioned taste aversion was significantly accelerated. We conclude that already aggregation of tau proteins not yet accompanied by massive formation of neurofibrillary tangles causes selective behavioral deficits.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056457     DOI: 10.1016/j.nbd.2003.11.020

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  28 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

3.  Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Authors:  Katharina Schindowski; Alexis Bretteville; Karelle Leroy; Séverine Bégard; Jean-Pierre Brion; Malika Hamdane; Luc Buée
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 4.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

Review 5.  Recent rodent models for Alzheimer's disease: clinical implications and basic research.

Authors:  Nady Braidy; Pablo Muñoz; Adrian G Palacios; Gloria Castellano-Gonzalez; Nibaldo C Inestrosa; Roger S Chung; Perminder Sachdev; Gilles J Guillemin
Journal:  J Neural Transm (Vienna)       Date:  2011-11-16       Impact factor: 3.575

Review 6.  Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.

Authors:  Anne Eckert; Kathrin L Schulz; Virginie Rhein; Jürgen Götz
Journal:  Mol Neurobiol       Date:  2010-03-09       Impact factor: 5.590

Review 7.  Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies.

Authors:  Miroslava Korenova; Zuzana Stozicka
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

8.  Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice.

Authors:  Anne Eckert; Susanne Hauptmann; Isabel Scherping; Jessica Meinhardt; Virginie Rhein; Stefan Dröse; Ulrich Brandt; Marcus Fändrich; Walter E Müller; Jürgen Götz
Journal:  J Mol Med (Berl)       Date:  2008-08-16       Impact factor: 4.599

9.  An update on the toxicity of Abeta in Alzheimer's disease.

Authors:  Jürgen Götz; Lars M Ittner; Nicole Schonrock; Roberto Cappai
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.

Authors:  Jürgen Götz; Naeman N Götz
Journal:  ASN Neuro       Date:  2009-11-09       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.